The medtech company Pexa has signed an agreement with a global pharmaceutical company for the delivery, installation and rental of ten PExA 2.1 systems for an international clinical study in idiopathic pulmonary fibrosis. This is according to a press release.The total order value amounts to approximately SEK 7.5 million over an agreement period of 18 months. Just over SEK 3.5 million is expected to be invoiced during the second quarter of 2026, followed by recurring quarterly rental income. Deliveries and installations are planned to begin during the third quarter of 2026.